The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study
Objective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and bone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study, 37 migraine patients took 600mg bid of Shi...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Evidence-Based Complementary and Alternative Medicine |
Online Access: | http://dx.doi.org/10.1155/2019/2363420 |
id |
doaj-658317799bda4365b068b23e9a448f49 |
---|---|
record_format |
Article |
spelling |
doaj-658317799bda4365b068b23e9a448f492020-11-25T01:37:50ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882019-01-01201910.1155/2019/23634202363420The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot StudyYesol Jung0Bohee Won1Mijung Lee2Jinyoung Chung3Sung Ju Han4Manho Kim5Department of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaDepartment of Veterinary Medicine, Kangwon National University, Chuncheon, Republic of KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaObjective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and bone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study, 37 migraine patients took 600mg bid of Shinbaro for 12 weeks. At 4-week intervals, the migraine frequency and the rescue medications frequency were measured from each patient’s headache diary. The modified Migraine Disability Assessment (MIDAS) questionnaires to assess migraine associated disabilities were also completed at each visit. The serum calcitonin gene-related peptide (CGRP) concentrations before and after 12 weeks of Shinbaro administration were compared. Results. The monthly migraine frequency was significantly reduced from 20.5 days at baseline to 16.4 days at week 12 (P =0.003), and 22% of the participants showed ≥ 50% reduction. The frequency reduction was observed by week 4 (P =0.035) and continuously occurred through week 8 (P =0.001) and week 12 (P =0.003). The rescue medications frequency also decreased significantly from 17.4 days at baseline to 13.2 days at week 12 (P =0.035). Lastly, the serum CGRP concentration dropped from 434.6 pg/mL at baseline to 371.4 pg/mL at week 12, which was statistically significant (P <0.001). Conclusions. Shinbaro demonstrated prophylactic effects in migraine patients, significantly reducing their mean migraine frequency, rescue medications frequency, and the serum CGRP concentration after 12 weeks of treatment. This study is registered in Clinical Research Information Service, Seoul National University Hospital Clinical Research Institute (IRB No. 1604-138-758).http://dx.doi.org/10.1155/2019/2363420 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yesol Jung Bohee Won Mijung Lee Jinyoung Chung Sung Ju Han Manho Kim |
spellingShingle |
Yesol Jung Bohee Won Mijung Lee Jinyoung Chung Sung Ju Han Manho Kim The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study Evidence-Based Complementary and Alternative Medicine |
author_facet |
Yesol Jung Bohee Won Mijung Lee Jinyoung Chung Sung Ju Han Manho Kim |
author_sort |
Yesol Jung |
title |
The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study |
title_short |
The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study |
title_full |
The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study |
title_fullStr |
The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study |
title_full_unstemmed |
The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study |
title_sort |
efficacy of shinbaro for the preventive treatment of migraine: a pilot study |
publisher |
Hindawi Limited |
series |
Evidence-Based Complementary and Alternative Medicine |
issn |
1741-427X 1741-4288 |
publishDate |
2019-01-01 |
description |
Objective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and bone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study, 37 migraine patients took 600mg bid of Shinbaro for 12 weeks. At 4-week intervals, the migraine frequency and the rescue medications frequency were measured from each patient’s headache diary. The modified Migraine Disability Assessment (MIDAS) questionnaires to assess migraine associated disabilities were also completed at each visit. The serum calcitonin gene-related peptide (CGRP) concentrations before and after 12 weeks of Shinbaro administration were compared. Results. The monthly migraine frequency was significantly reduced from 20.5 days at baseline to 16.4 days at week 12 (P =0.003), and 22% of the participants showed ≥ 50% reduction. The frequency reduction was observed by week 4 (P =0.035) and continuously occurred through week 8 (P =0.001) and week 12 (P =0.003). The rescue medications frequency also decreased significantly from 17.4 days at baseline to 13.2 days at week 12 (P =0.035). Lastly, the serum CGRP concentration dropped from 434.6 pg/mL at baseline to 371.4 pg/mL at week 12, which was statistically significant (P <0.001). Conclusions. Shinbaro demonstrated prophylactic effects in migraine patients, significantly reducing their mean migraine frequency, rescue medications frequency, and the serum CGRP concentration after 12 weeks of treatment. This study is registered in Clinical Research Information Service, Seoul National University Hospital Clinical Research Institute (IRB No. 1604-138-758). |
url |
http://dx.doi.org/10.1155/2019/2363420 |
work_keys_str_mv |
AT yesoljung theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT boheewon theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT mijunglee theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT jinyoungchung theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT sungjuhan theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT manhokim theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT yesoljung efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT boheewon efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT mijunglee efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT jinyoungchung efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT sungjuhan efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy AT manhokim efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy |
_version_ |
1725057036243173376 |